PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...
Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...
In addition, ABILIFY is available in a 1 mg/mL nonrefrigerated Oral Solution and as a single-dose, ready-to-use solution for intramuscular injection 7.5 mg/mL. In adult patients, the recommended ...
PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...
According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...
ABILIFY MAINTENA® (aripiprazole). Please see IMPORTANT SAFETY INFORMATION, including BOXED WARNING for INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS, for ABILIFY ASIMTUFII ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A long-acting ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback